Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Glycerol phenylbutyrate granted orphan drug designation for treatment of STXBP1 developmental and epileptic encephalopathy

Stockholm, October 20, 2023 – Immedica today announces that the European Commission has granted an orphan designation for glycerol phenylbutyrate in STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), following positive opinion from EMA’s Committee for Orphan Medicinal Products (COMP). Orphan designation is granted to medicines that treat, prevent, or diagnose a life-threatening or chronically debilitating rare disease, with a prevalence in the EU of below 5 in 10,000, and with either no satisfactory method of diagnosis, prevention or treatment or with significant benefit to

BioStock: WntResearch recruits first patient in restart of NeoFox

After receiving the green light for its redesigned study plan for NeoFox this summer, WntResearch have announced the recruitment of the first patient. The revised study is now officially underway with the first part expected to take about six months to complete. BioStock contacted CEO Pernilla Sandwall for a comment on this milestone.Read the article at biostock.se: https://www.biostock.se/en/2023/10/wntresearch-rekryterar-forsta-patienten-i-aterstarten-av-neofox/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Positive preclinical results for Curasight in lung cancer

Biotech company Curasight recently announced positive preclinical results for uTREAT in the treatment of non-small cell lung cancer, showing that uTREAT effectively inhibits tumor growth. These findings comes on the heels of recent positive preclinical results in the treatment of glioblastoma, reinforcing the hypothesis that uTREAT is not cancer type specific, but has the potential to treat a broader spectrum of solid tumors.Read the interview with Curasights CEO Ulrich Krasilnikoff at biostock.se: https://www.biostock.se/en/2023/10/positive-preclinical-results-for-curasight-in-lung-

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 174 - 20 OCTOBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

TradeVenue releases first analysis on White Pearl Technology Group

Swedish investor community, TradeVenue, released an in-depth analysis of the global IT-service provider, White Pearl Technology Group (WPTG) listed on Nasdaq First North Growth Market since the 29[th] of June 2023. The report highlights a significant upside potential in the consistent growth of WPTG."We have today published an initiating report on White Pearl Technology Group (WPTG). WPTG is an extremely fast-growing Group offering a comprehensive portfolio of solutions including IT consulting, infrastructure services, proprietary software products, system integration, cybersecurity, cloud

Preliminary results from Booster trial with Diamyd® provide additional support for intralymphatic injections

Preliminary results from the open-label clinical trial DIAGNODE-B provide additional support for the safety and feasibility of intralymphatic booster injections of Diamyd[®], showing only a small decline in stimulated endogeous insulin production one year following the additional injection and up to 8 years from type 1 diabetes diagnosis.“These results are valuable as they continue to support the feasibility of additional intralympahtic injections of Diamyd and a mild disease progression”, says Johnny Ludvigsson, Professor at Linköping University and Sponsor's representative of the trial.

Smoltek answers questions after investor event in Lund on October 9

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB ("Smoltek") follows up the presentation at the investor event, Aktiedagen in Lund on October 9, with a post on the company's IR blog where CEO Håkan Persson answers questions about the content of the presentation.“The investor event Aktiedagen is a good opportunity for us to tell how we see our market, both demand and competition, as well as tell how we intend to commercialize our technology. But it is not possible to go in-depth in just

Lindex accelerates circularity with new textile-to-textile fibre

Lindex takes further steps and accelerates its commitment to circularity through a long-term agreement with Finnish Infinited Fiber Company and its patented fibre Infinna™, made from 100 per cent post-consumer textile waste. Partnering with Infinited Fiber is an important step in Lindex’s transformation to a more sustainable and circular assortment with raw material from textile waste. ‘With only a fraction of all textile waste in the world being recycled there must be a change and we are happy to see players like Infinited Fiber enabling this. Infinited Fiber has the technology

Aiforia initiates path to secure its first regulatory approval in the United States – application to the FDA anticipated in 2024

Aiforia Technologies Plc, Press Release, October 20, 2023 at 10:00 a.m. EEST. Aiforia Technologies Plc initiates a path to secure regulatory approval for its first product in the United States.The Food and Drug Administration (FDA) is responsible for market surveillance of medical devices in the U.S. Together with a local consulting company, Aiforia is planning and implementing the necessary steps to submit an application to the FDA during 2024.   “The demand for digital pathology image analysis in clinical diagnostics is increasing in the U.S. We want to ensure that we are well

Publishing of Stockmann’s Interim Management Statement for January–September 2023

STOCKMANN plc, Press release 20.10.2023 at 10:00 EEST Publishing of Stockmann’s Interim Management Statement for January–September 2023 Stockmann plc will publish its Interim Management Statement for January–September 2023 on Friday 27 October 2023 at 8:00 EEST. A press and analyst briefing will be held in English the same day at 10:00 EEST as a live webcast that can be followed via this link.  The recording and presentation material will be available on the company's website after the event. Further information:

Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05

Oslo, 20 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Øystein Rekdal, Chief Executive Officer, and Graeme Currie, Chief Development Officer, will host a webcast for investors and analysts on Monday October 23 at 15:30 CET, in conjunction with the ESMO 2023 Congress.The webcast is being held to provide further insights and additional information about the preliminary data from the ATLAS-IT-05 study, that is being presented in a poster session at ESMO, and the associated press release

We are proud to announce that TYRI has been named the ‘Best Optics & Photonics Company of the Year 2023’ by PhotonicSweden

Christian Wadell, Global R&D Manager at TYRI, and Stuart Campbell, Optics Specialist at TYRI, were proud to receive the prestigious award during PhotonicSweden's conference this week (October 17–19)."We are of course very happy and grateful for this fine award. It is further proof that we can challenge the industry and that our research and development creates products that make a difference for both the industry and the end user," says Martin Karlberg, CEO of TYRI. PhotonicSweden said in their statement, “By awarding TYRI Sweden AB the award as the best optics and photonics company

Layer Group acquires Golvimporten to strengthen its offering in surface services

Layer Group is continuing in its drive to be a complete surface services supplier with the acquisition of the Borås company Golvimporten. Expanding to include Golvimporten is a major investment in Layer Group’s flooring segment, and in line with the group’s strategy for growth in surface services. “Golvimporten is impressive, their CEO Pierre Nilsson and his management team run a company based on skilled employees, good profitability and smart business. Their expertise will be an important asset for Layer Group, and Golvimporten is exactly the right company for the vision we have

Arise announces divestment of Fasikan to SCA

Arise AB (publ) (”Arise”) has entered into an agreement with SCA, Europe’s largest private forest owner, for the sale of the 105 MW wind farm Fasikan (the ”Project”). Closing occured today. The transaction covers all the shares in Fasikan Vind AB at an enterprise value of approximately SEK 1.6 billion. The project is sold in ready-to-build status at a share purchase price of approximately SEK 125 million. The purchase price includes a variable portion which is dependent upon how construction of the project progresses in relation to budget. Furthermore, Arise will manage the construction

Alligo consolidates its concept brands in the Nordic region

Alligo is taking the next step to integrate its operations by having one primary brand on each market. In Sweden, it will be Swedol that customers see in stores and online, while on the Norwegian and Finnish markets it will be TOOLS.As a result, the company’s Grolls stores will be changing their name to Swedol in Sweden and to TOOLS in Finland. In Norway, all the Univern stores will be brought together under the TOOLS brand.    -         Since Swedol, TOOLS, Grolls and Univern were formed into a single group in 2020, we have been working to create a common platform for all our concept

Rejlers responsible for the system architecture in strategically important port expansion in Luleå

To meet the industrial development and sustainable transformation in northern Sweden, the Port of Luleå is now building the New Port of Luleå. Rejlers is the project manager responsible for the system architecture that will enable a high degree of automation for the port facility.The new port that is being built in Luleå will have a completely new port area of 750,000 square meters and is a strategically important project to be able to carry out all planned industrial investments in northern Sweden. Rejlers is the project manager responsible for establishing a modern system architecture

Publication of Raute Corporation’s Q3 2023 Interim Report and invitation to a briefing

Raute Corporation, Investor news, 20 October 2023  Publication of Raute Corporation’s Q3 2023 Interim Report and invitation to a briefing   Raute Corporation will publish its Interim Report for January 1−September 30, 2023 on Thursday, October 26, 2023 at about 8:30 a.m. Finnish time. A briefing for analysts, investors and the media will be organized on the same day October 26, 2023 at 2:00−3:00 p.m.   Venue: Scandic Simonkentta Hotel, Simonkatu 9, Helsinki.   Please inform of your participation in the briefing at the latest on Tuesday, October 24, 2023 to Raute

BioArctic presents Nomination Committee

Stockholm, Sweden, October 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on June 1, 2023, adopted an instruction regarding the appointment of the Nomination Committee. Pursuant to this instruction the company shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2023, as well as the Chairman of the Board (convener).September 30, 2023, the three largest shareholders were Demban AB,

Last day of subscription of units in Risk Intelligence A/S ongoing rights issue and guidance on how to subscribe

Risk Intelligence A/S ("Risk Intelligence" or the "Company") announce that Tuesday, 24 October 2023, is the last day for subscription in Risk Intelligences ongoing rights issue of units of approximately DKK 18.4 million (the "Rights Issue").  The last day of trading in unit rights on Spotlight Stock Market is today, the 20 October 2023. Note that some banks and brokers have an earlier date for subscription than the 24 October. Current shareholders or new investors should therefore examine with their bank or broker whether they are using an earlier last day of subscription.There are two

Warrants of series TO2 were subscribed to approximately 1.65 percent and Pharmacolog i Uppsala AB receives approximately SEK 6.6 thousand

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEELAND, RUSSIA, SCHWEIZ, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Pharmacolog i Uppsala AB (publ) ("Pharmacolog" or "the Company") today announces the outcome of the exercise of warrants of series TO2, which were issued in

Arise and SCA cooperate in development of approx. 1,000 MW of wind power

Arise AB (publ) (”Arise”) today entered into a partnership agreement with SCA, Europe’s largest private forest owner, regarding the development of onshore wind power on parts of SCA’s land in Sweden. The development partnership with SCA is another step in Arise’ focus to deepen cooperations with landowners in the company’s core markets with the aim developing and constructing new wind power. Arise and SCA have identified six concrete land areas with an estimated total potential of approximately 1,000 MW. The identified land areas are believed to have good prospects to realize projects on

SCA to build new wind farm and increases the degree of self-sufficiency in electricity

SCA is increasing its degree of self-sufficiency in electricity for its own industry by acquiring Fasikan Vind AB, a wind power project located on SCA's land in the Bräcke municipality of Jämtland County. The seller is Arise AB.  The acquisition is in line with SCA's wind power strategy, which includes leasing land to wind power operators, operating own wind farms, and project development for own operation or for sale.  Construction of the wind farm will begin in November 2023 and is planned to be operational at the beginning of 2026. The wind farm will consist of 15 turbines with

Nomination Committee appointed ahead of the 2024 Annual General Meeting

In accordance with the guidelines adopted by the Annual General Meeting on May 4, 2017, GARO has established a Nomination Committee. The Nomination Committee is to prepare and make proposals to the 2024 Annual General Meeting concerning:  · the Chairman of the Annual General Meeting; · candidates for the post of Chairman and other members of the Board; · election and remuneration of the company’s auditors; · board fees and distribution between the Chairman and other members as well as remuneration for committee work; and · any changes to the instructions for the

Episurf Medical: 510(k) submission for big toe implant today

Episurf Medical (NASDAQ: EPIS B) today announces that a 510(k) filing to the US FDA for market clearance of the company’s toe implant for the 1[st] MTP joint is being submitted today. The submission will now undergo a review process and the company aims to receive clearance to be able to launch the product on the US market during 2024. “This is a significant milestone which we have been looking forward to for quite some time. With this product, we are entering into a fast-moving and fast-growing market segment, with a totally unique solution. This is also the last piece of the puzzle of

There are no items matching the current filter
There are no more items matching the current filter
Back to top